Lupus cystitis, a severe complication of systemic lupus erythematosus (SLE), presents considerable treatment challenges.
Purpose
This case report describes the use of telitacicept in treating severe SLE with lupus cystitis.
Research Design
A single patient with lupus cystitis.
Study Sample
A patient with symptoms including frequent urination, urgency, and acute urinary retention.
Data Collection and Analysis
Initial treatments included corticosteroid pulse therapy, immunoglobulin, and cyclophosphamide, which improved laboratory indicators but failed to alleviate symptoms of urinary retention. The patient was then treated with telitacicept.
Results
Significant alleviation of urinary retention was observed shortly after incorporating telitacicept into the treatment regimen. The patient's condition remained stable with no relapse during the subsequent 10 months of follow-up.
Conclusions
This case highlights the therapeutic potential of telitacicept for SLE patients who are unresponsive to conventional therapies, particularly those with severe manifestations such as lupus cystitis.
SiegelCHSammaritanoLR. Systemic lupus erythematosus: a review. JAMA2024; 331(17): 1480–1491.
2.
WeismanMHMcDanaldECWilsonCB. Studies of the pathogenesis of interstitial cystitis, obstructive uropathy, and intestinal malabsorption in a patient with systemic lupus erythematosus. Am J Med1981; 70(4): 875–881.
3.
LiuBFuDW. Low compliance bladder plays a role in hydronephrosis in lupus cystitis: a case report. Lupus2014; 23(8): 829–832.
4.
LiZXuDWangZ, et al.Gastrointestinal system involvement in systemic lupus erythematosus. Lupus2017; 26(11): 1127–1138.
5.
DhillonS. Telitacicept: first approval. Drugs2021; 81(14): 1671–1675.
6.
ShiFXueRZhouX, et al.Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol2021; 43(6): 666–673.
7.
CaiSHuZChenY, et al.BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept. Ann Rheum Dis2023; 82(6): 881–883.
8.
LvJLiuLHaoC, et al.Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep2023; 8(3): 499–506.
9.
WuDLiJXuD, et al.Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis2024; 83(4): 475–487.
10.
XuDFangJZhangS, et al.Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial. Rheumatology2024; 63(3): 698–705.
11.
KohJHLeeJJungSM, et al.Lupus cystitis in Korean patients with systemic lupus erythematosus: risk factors and clinical outcomes. Lupus2015; 24(12): 1300–1307.
12.
SantacruzJCPulidoSArzuagaA, et al.Lupus cystitis, from myth to reality: a narrative review. Cureus2021; 13(12): e20409.
13.
SegawaCWadaTFuruichiK, et al.Steroid pulse therapy in lupus cystitis. Intern Med1996; 35(2): 155–158.
14.
MukhopadhyaySJanaSRoyMK, et al.Lupus cystitis: an unusual presentation of systemic lupus erythematosus. Indian J Nephrol2014; 24(5): 308–311.
15.
ClemensJQEricksonDRVarelaNP, et al.Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol2022; 208(1): 34–42.
16.
MoldwinRMNurseyVYaskivO, et al.Immune cell profiles of patients with interstitial cystitis/bladder pain syndrome. J Transl Med2022; 20(1): 97.
17.
AbeYKawamataNMakiyamaA, et al.In lupus cystitis, is the urinary tract dilated or obstructed? Immunity. Immun Inflamm Dis2023; 11(2): e777.
18.
Alarcón-SegoviaDAbud-MendozaCReyes-GutiérrezE, et al.Involvement of the urinary bladder in systemic lupus erythematosus. A pathologic study. J Rheumatol1984; 11(2): 208–210.
19.
PengLJinXLiBY, et al.Integrating single-cell RNA sequencing with spatial transcriptomics reveals immune landscape for interstitial cystitis. Signal Transduct Target Ther2022; 7(1): 161.
20.
SuFZhangWMengL, et al.Multimodal single-cell analyses outline the immune microenvironment and therapeutic effectors of interstitial cystitis/bladder pain syndrome. Adv Sci2022; 9(18): e2106063.
21.
Carvajal AlegriaGGazeauPHillionS, et al.Could lymphocyte profiling be useful to diagnose systemic autoimmune diseases?Clin Rev Allergy Immunol2017; 53(2): 219–236.
22.
ZengLYangKWuY, et al.Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases. J Autoimmun2024; 148: 103291.
23.
XuLSongXDaiQ, et al.Successful treatment of refractory cystitis associated with systemic lupus erythematosus with Belimumab. Int Immunopharmacol2021; 96: 107574.
24.
FanCYangTZhengS, et al.Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: a real-life, single-center observational study. Front Immunol2024; 15: 1423035.
25.
WuDLiJXuD, et al.Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis2024; 83(4): 475–487.
26.
LvJLiuLHaoC, et al.Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep2023; 8(3): 499–506.
